North Carolina Headlines

(Albany, US) September 29, 2026 – DelveInsight’s “Lupus Nephritis Pipeline Insight, 2026” report provides comprehensive insights about 35+ companies and 42+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Lupus Nephritis Treatment Landscape @ https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight

Key Takeaways from the Lupus Nephritis Pipeline Report

• DelveInsight’s Lupus Nephritis pipeline report depicts a robust space with 35+ active players working to develop 42+ pipeline therapies for Lupus Nephritis treatment.

• The leading Lupus Nephritis Companies include Novartis, Q32 Bio, Kyverna Therapeutics, Cabaletta Bio, Nkarta, Inc., AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics, and others.

• Promising Lupus Nephritis Pipeline Therapies such as Ianalumab, ADX-097, KYV-101, CABA-201, NKX019, Anifrolumab, Obinutuzumab, Telitacicept, Efgartigimod alfa, Iptacopan, and others.

• The companies which have their Lupus Nephritis drug candidates in the most advanced stage, i.e. Phase III, include Novartis.

Gain in-depth knowledge of key Lupus Nephritis clinical trials, emerging drugs, and market opportunities @ Lupus Nephritis Clinical Trials Assessment

Lupus Nephritis Overview

Lupus Nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE), an autoimmune disorder marked by loss of immune tolerance to endogenous nuclear material, resulting in systemic autoimmunity that damages various tissues and organs. The overall incidence and prevalence of SLE range from 7.4 to 159.4 cases per 100,000 people and from 1.4% to 21.9%, respectively. According to the National Kidney Foundation, lupus nephritis is a form of glomerulonephritis that causes inflammation of the small blood vessels that filter waste in the kidney (glomeruli), and sometimes the kidneys themselves; histologically, LN is classified into six distinct classes representing different manifestations and severity of renal involvement in SLE.

Lupus nephritis can cause permanent kidney damage, known as chronic kidney disease (CKD). The most serious type, proliferative nephritis, can cause scarring of the kidneys that prevents them from working properly, and chronic kidney disease that worsens to the point the kidneys stop working is called kidney failure or end-stage renal disease (ESRD). Major risk factors associated with LN include gender, ethnicity, genetic factors, and environmental factors, and it is typically treated with drugs that block the body’s immune system, including glucocorticoids and immunosuppressive agents such as cyclophosphamide or mycophenolate mofetil (MMF).

A variety of pathogenic mechanisms are involved in the development of lupus nephritis, with its extra-renal etiology based on a combination of genetic variations that alter the mechanisms normally ensuring immune tolerance to nuclear autoantigens. As renal immunopathology progresses, tertiary lymphoid tissue formation and local antibody production add to intrarenal complement activation. Diagnosing lupus nephritis requires clinicians to maintain a high index of suspicion in patients with known SLE and worsening renal function; persistent eosinophilia can also occur, and patients with SLE need to be routinely tested for early detection of renal impairment.

Treatment of lupus nephritis aims to reduce symptoms, prevent disease progression, and maintain kidney function; there is no cure, but various treatments help achieve these goals. Medications such as steroids (prednisone), immunosuppressive drugs (cyclophosphamide, mycophenolate mofetil), and monoclonal antibodies (rituximab, belimumab) are commonly prescribed, alongside supportive treatments such as diet changes, blood pressure medications (ACE inhibitors, ARBs), and diuretics to manage symptoms and protect kidney function.

Lupus Nephritis Emerging Drugs Profile

• Ianalumab: Novartis

Ianalumab is a humanized monoclonal antibody targeting the BAFF receptor (B-cell activating factor), designed to treat lupus nephritis by depleting B cells and modulating the immune response to reduce kidney inflammation and damage. Early clinical studies suggest ianalumab may improve renal outcomes by controlling disease activity in patients with lupus nephritis. The drug is currently in the Phase III stage of its development for the treatment of lupus nephritis.

• ADX-097: Q32 Bio

ADX-097 is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade — a key differentiator from current complement therapeutics. Q32 Bio completed a first-in-human, Phase I ascending-dose clinical study of ADX-097 in healthy volunteers, with results demonstrating a favorable tolerability and immunogenicity profile across all single and multiple dose cohorts; weekly subcutaneous dosing met exposures for predicted complete complement inhibition in tissue with no systemic inhibition. Currently, the drug is in the Phase II stage of its development for the treatment of Lupus Nephritis.

• KYV-101: Kyverna Therapeutics

KYV-101 is an autologous version of a novel, fully human, clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for B cell-driven autoimmune diseases such as lupus nephritis. It is currently in the Phase I/II stage of development for the treatment of Lupus Nephritis.

• CABA-201: Cabaletta Bio

CABA-201 is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain. Cabaletta is advancing its RESET™ (REstoring SElf-Tolerance) Phase I/II clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis, with potential application across a broad range of other autoimmune diseases. It is currently in the Phase I/II stage of development for the treatment of Lupus Nephritis.

NKX019: Nkarta, Inc.

NKX019 is designed to target CD19-positive B cells, which play a significant role in the pathogenesis of autoimmune diseases like lupus. The therapy uses NK cells derived from healthy donors that are genetically modified to enhance their ability to eliminate these B cells, and is engineered to express a membrane-bound form of interleukin-15, which may improve NK-cell persistence and activity without the extensive cytokine support typically required by other therapies. It is currently in the Phase I stage of development for the treatment of Lupus Nephritis.

The Lupus Nephritis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis, with aggregate therapies developed by each company.

• It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Lupus Nephritis treatment.

• Lupus Nephritis Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.

• Lupus Nephritis drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.

• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the Lupus Nephritis market.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Lupus Nephritis Unmet Needs

Lupus Nephritis Companies

Novartis, Q32 Bio, Kyverna Therapeutics, Cabaletta Bio, Nkarta, Inc., AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics, and others.

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Lupus Nephritis Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Transform your understanding of the Lupus Nephritis Pipeline! @ Lupus Nephritis Market Drivers and Barriers, and Future Perspectives

Scope of the Lupus Nephritis Pipeline Report

• Coverage- Global

• Lupus Nephritis Companies- Novartis, Q32 Bio, Kyverna Therapeutics, Cabaletta Bio, Nkarta, Inc., AstraZeneca, Hoffmann-La Roche, Qilu Pharmaceutical, BeiGene, RemeGen, Argenx, Jiangsu Lianhuan Pharmaceutical, Century Therapeutics, Yake Biotechnology, Qyuns Therapeutics, Resolve Therapeutics and others.

• Lupus Nephritis Pipeline Therapies- Ianalumab, ADX-097, KYV-101, CABA-201, NKX019, Anifrolumab, Obinutuzumab, QLG1074, Zanubrutinib, Telitacicept, Efgartigimod alfa, RYSW01, Iptacopan, ANX009, CNTY-101, CD19/BCMA CAR T-cells, QX002N, RSLV-145 and others.

• Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Lupus Nephritis Pipeline Analysis Today! @ Lupus Nephritis Drugs and Companies

Table of Contents

• Introduction

• Executive Summary

• Lupus Nephritis: Overview

• Pipeline Therapeutics

• Comparative Analysis

• Therapeutic Assessment

• Lupus Nephritis: DelveInsight’s Analytical Perspective

• Late Stage Products (Phase III)

• Mid Stage Products (Phase II)

• Early Stage Products (Phase I)

• Preclinical and Discovery Stage Products

• Inactive Products

• Lupus Nephritis Key Companies

• Lupus Nephritis Key Products

• Lupus Nephritis: Unmet Needs

• Lupus Nephritis: Market Drivers and Barriers

• Lupus Nephritis: Future Perspectives and Conclusion

• Lupus Nephritis Analyst Views

• Lupus Nephritis Key Companies

• Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight